Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Szubert

Showing results (11-20 of 46) with videos related to

Pageof 5
Sort By:
PLOS Global Public Health|February 17, 2026
Longitudinal changes in bone mineral density among children living with HIV over 96 weeks following switch to second-line antiretroviral therapy in UgandaEva Natukunda, Erisa Mwaka, Alexander J Szubert, et al.
AIDS (London, England)|July 21, 2015
Single-dose nevirapine exposure does not affect response to antiretroviral therapy in HIV-infected African children aged below 3 yearsPhilippa Musoke, Alexander J Szubert, Victor Musiime, et al.
BMC Pediatrics|July 4, 2025
Comparison between dual energy X-ray absorptiometry and calcaneal quantitative ultrasound for determining bone mineral density in children living with HIV in uganda: A cross- sectional studyEva Natukunda, Alexander J Szubert, Alasdair Bamford, et al.
Blood|April 14, 2012
Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX TrialGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Haematologica|April 23, 2010
The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significanceFiona M Ross, Laura Chiecchio, GianPaolo Dagrada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2013
Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatmentGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 6, 2023
Pharmacokinetic Data of Dolutegravir in Second-line Treatment of Children With Human Immunodeficiency Virus: Results From the CHAPAS4 TrialLisanne A H Bevers, Hylke Waalewijn, Alexander J Szubert, et al.
The Pediatric Infectious Disease Journal|July 29, 2014
Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapyMutsawashe Bwakura-Dangarembizi, Victor Musiime, Alexander J Szubert, et al.
Nature Communications|June 29, 2024
Biomarkers of mortality in adults and adolescents with advanced HIV in sub-Saharan AfricaVictor Riitho, Roisin Connon, Agnes Gwela, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2010
Heterogeneity in the prognostic significance of 12p deletion and chromosome 5 amplification in multiple myelomaWilliam Tapper, Laura Chiecchio, Gian Paolo Dagrada, et al.
Pageof 5

Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
PLOS Global Public Health|February 17, 2026
Longitudinal changes in bone mineral density among children living with HIV over 96 weeks following switch to second-line antiretroviral therapy in UgandaEva Natukunda, Erisa Mwaka, Alexander J Szubert, et al.
AIDS (London, England)|July 21, 2015
Single-dose nevirapine exposure does not affect response to antiretroviral therapy in HIV-infected African children aged below 3 yearsPhilippa Musoke, Alexander J Szubert, Victor Musiime, et al.
BMC Pediatrics|July 4, 2025
Comparison between dual energy X-ray absorptiometry and calcaneal quantitative ultrasound for determining bone mineral density in children living with HIV in uganda: A cross- sectional studyEva Natukunda, Alexander J Szubert, Alasdair Bamford, et al.
Blood|April 14, 2012
Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX TrialGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Haematologica|April 23, 2010
The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significanceFiona M Ross, Laura Chiecchio, GianPaolo Dagrada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2013
Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatmentGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 6, 2023
Pharmacokinetic Data of Dolutegravir in Second-line Treatment of Children With Human Immunodeficiency Virus: Results From the CHAPAS4 TrialLisanne A H Bevers, Hylke Waalewijn, Alexander J Szubert, et al.
The Pediatric Infectious Disease Journal|July 29, 2014
Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapyMutsawashe Bwakura-Dangarembizi, Victor Musiime, Alexander J Szubert, et al.
Nature Communications|June 29, 2024
Biomarkers of mortality in adults and adolescents with advanced HIV in sub-Saharan AfricaVictor Riitho, Roisin Connon, Agnes Gwela, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2010
Heterogeneity in the prognostic significance of 12p deletion and chromosome 5 amplification in multiple myelomaWilliam Tapper, Laura Chiecchio, Gian Paolo Dagrada, et al.
Pageof 5